Want to see CDXS full AI Analyst Report?
CDXS Stock Chart & Stats
$1.48
$0.10(7.09%)
At close: 4:00 PM EDT
$1.48
$0.10(7.09%)
Day’s Range― - ―
52-Week Range$0.96 - $3.87
Previous CloseN/A
Volume846.44K
Average Volume (3M)1.15M
Market Cap
$161.34M
Enterprise Value$155.29
Total Cash (Recent Filing)$65.56M
Total Debt (Recent Filing)$72.90M
Price to Earnings (P/E)―
Beta2.31
Next Earnings
Oct 29, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding107,563,230
10 Day Avg. Volume1,704,148
30 Day Avg. Volume1,146,380
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.81
Price to Sales (P/S)2.02
P/FCF Ratio-5.96
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.50Price Target Upside339.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.39
Revenue Forecast (FY)$74.10M
Bulls Say, Bears Say
Bulls Say
High Gross Margins / Unit EconomicsVery high product gross margins (TTM ~82%, Q2 product margin 73%) indicate strong unit economics and pricing power in enzyme manufacturing. Sustained high margins support profitable scale if commercial volumes and fixed-cost absorption improve, underpinning long-term margin sustainability.
Technical Differentiation: ECOsynthesisProprietary ECOsynthesis advances (stereochemistry control, Starterless initiation) create a durable competitive moat for siRNA and oligo manufacturing. Technology-led differentiation increases partner stickiness, supports higher-value collaborations, and can translate into recurring licensing and royalty streams over time.
Improved Liquidity And Funding RunwayA recent $25M financing materially strengthens the cash runway (pro‑forma ~$79.8M) and funds planned GMP buildout. Improved liquidity reduces near-term refinancing risk, allowing management to focus on industrialization, tech transfers and commercial conversion over the next 2–3 years.
Bears Say
Sustained Operating Losses & Cash BurnPersistent negative operating and free cash flow and sizable net losses show the business has not yet reached self-sustaining profitability. Continued reliance on external capital raises dilution and execution risk if revenue conversion or margin expansion falls short over the medium term.
Elevated Leverage And Weaker Balance SheetRapidly increasing leverage materially reduces financial flexibility and raises servicing obligations, constraining the company's ability to fund capex or absorb setbacks. Higher debt relative to a shrinking equity base amplifies refinancing and covenant risks during slower revenue periods.
Revenue Lumpiness & Execution ConcentrationCommercial upside is concentrated in converting a few CDMO assessments and industrializing ECOsynthesis to kilogram scale. Revenue cadence and forecasting remain volatile; failure to industrialize or secure long-term CDMO contracts would materially impair durable revenue growth and cash generation.
Codexis News
CDXS FAQ
What was Codexis’s price range in the past 12 months?
Codexis lowest stock price was $0.96 and its highest was $3.87 in the past 12 months.
What is Codexis’s market cap?
Codexis’s market cap is $161.34M.
When is Codexis’s upcoming earnings report date?
Codexis’s upcoming earnings report date is Oct 29, 2026 which is in 78 days.
How were Codexis’s earnings last quarter?
Codexis released its earnings results on Aug 11, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.142 by $0.012.
Is Codexis overvalued?
According to Wall Street analysts Codexis’s price is currently Undervalued.
Does Codexis pay dividends?
Codexis does not currently pay dividends.
What is Codexis’s EPS estimate?
Codexis’s EPS estimate is -0.09.
How many shares outstanding does Codexis have?
Codexis has 107,563,230 shares outstanding.
What happened to Codexis’s price movement after its last earnings report?
Codexis reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.142. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Codexis?
Currently, no hedge funds are holding shares in CDXS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Codexis Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.50 (339.19% Upside)
$6.50 (339.19% Upside)
Blogger Sentiment
Bearish
CDXS Sentiment 100%
Sector Average 62%
Sector Average 62%
Insider Transactions
Sold Shares
Worth $6.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.37%
Trailing 12-Months
Company Description
Codexis
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
CDXS Company Deck
CDXS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a predominantly positive strategic and technical narrative: clear technology milestones (stereochemistry control, Starterless initiation), progressing scale demonstrations (hundreds of grams toward kilogram scale), active CDMO and biopharma engagements, improving product gross margin (73%) and disciplined expense reductions. Financially, the company showed a modest year-over-year revenue decline in the quarter, a pre-financing drop in cash balance, and an ongoing net loss. These negatives are mitigated by a successful $25M financing that restores pro forma cash to ~$79.8M and management's stated cash runway through 2028, plus reiterated 2026 revenue guidance ($70M–$76M). The primary remaining risks are revenue lumpiness, the need to convert pilot/tech-transfer activity into firm commercial contracts, and successfully industrializing ECOsynthesis at commercial scale. On balance, highlights (technical differentiation, commercial engagement, margin improvement, financing and runway) outweigh the lowlights (quarterly revenue decline, cash drawdown prior to financing, execution risk), supporting a constructive view of progress and prospects.View all CDXS earnings summariesCDXS Stock 12 Month Forecast
Average Price Target
$6.50
▲(339.19% Upside)
Technical Analysis
Ownership Overview
11.47% Insiders
12.81% Mutual Funds
5.94% Other Institutional Investors
61.12% Public Companies and
Individual Investors